Shanghai Shenqi Pharmaceutical Investment Management600613.SHValuation Analysis

As of Oct 19, 2026, Shanghai Shenqi Pharmaceutical Investment Management (600613.SH) trades at a P/E of 156.00x, P/B of 1.87x, P/S of 2.52x, and a dividend yield of 0.94%.
Longitudinal percentile comparison: P/E sits at the 97th percentile over the trailing 10Y window (vs. 92nd percentile over 3Y); P/B sits at the 81st percentile over the trailing 10Y window (vs. 89th percentile over 3Y); P/S sits at the 79th percentile over the trailing 10Y window (vs. 90th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 89th percentile within its industry and the 88th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.94%, ranking at the 77th percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 15.8 points apart — worth checking the full percentile matrix on this page for the complete picture. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Shanghai Shenqi Pharmaceutical Investment Management operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.